MMP and TIMP play an important role in the degradation of extracellular matrix components which are essential for tumor growth, invasion and metastasis. Aim of this research was to assess MMP3 and TIMP3 as prognostic factors among patients with ovarian cancer.
It was found that high levels of output MMP3 correlated with shortened overall survival time of patients by 9.7 months. In addition, it has been shown that high concentrations of output MMP3 were significantly associated with a shorter disease free time in median concentrations implemented p = 0.0059. Statistically significant dependence has been shown between an average concentration of TIMP3 protein to the overall survival of patients. The higher output concentration of TIMP3, the longer patients’ survival by 8.9 month. In addition, it was found that high TIMP3 concentrations output were associated with a significantly longer disease free duration at a median concentrations p = 0.007.
Preliminary research shows that output levels of MMP3 and TIMP3 proteins correlate with overall survival of patients. In some cases also time free of illness.
Chudecka-Glaz A, Cymbaluk-Ploska A, Luterek-Puszynska K, Menkiszak J. Diagnostic usefulness of the risk of ovarian malignancy algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125. Oncol Lett. 2016;12(5):3101–14. PubMedPubMedCentral
Pelissier A, Bonneau C, Chereau E, DE LA Motte Rouge T, Fourchotte V, Darai E, et al. Dynamic analysis of CA125 decline during Neoadjuvant chemotherapy in patients with epithelial ovarian cancer as a predictor for platinum sensitivity. Anticancer Res. 2016;36(4):1865–71. PubMed
Cymbaluk-Ploska A, Chudecka-Glaz A, Surowiec A, Pius-Sadowska E, Machalinski B, Menkiszak J. MMP3 in comparison to CA 125, HE4 and the ROMA algorithm in differentiation of ovarian tumors. Asian Pac J Cancer Prev. 2016;17(5):2597–603. PubMed
Ozalp S, Tanir HM, Yalcin OT, Kabukcuoglu S, Oner U, Uray M. Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol. 2003;24(5):417–20. PubMed
Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer. 2003;39(13):1948–56. CrossRefPubMed
- Suitability assessment of baseline concentration of MMP3, TIMP3, HE4 and CA125 in the serum of patients with ovarian cancer
- BioMed Central
Neu im Fachgebiet Gynäkologie und Geburtshilfe
Meistgelesene Bücher aus dem Fachgebiet
e.Med Kampagnen-Visual, Mail Icon II